Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Background
MGD014 is an investigational bispecific DART® molecule that targets the envelope protein of HIV-infected cells (Env) and T cells, via their CD3 component, to redirect the immune system’s T cells to kill HIV-infected cells. DART molecules could be used independently or become a key part of a “shock-and-kill” strategy in conjunction with HIV latency-reversing agents currently under development. MGD014 is MacroGenics’ first clinical DART molecule designed to target virus-infected cells.
Clinical Development
MGD014 is being evaluated in a Phase 1 dose escalation study. MGD014 is being developed under contract number HHSN272201500032C awarded to MacroGenics in September 2015 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Our Rights
MacroGenics retains full worldwide rights to MGD014.
Learn More:
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.